Generative AI: Generative AI creates novel molecules with desired properties, expanding chemical exploration beyond existing compound libraries and accelerating early-stage drug design.
Protein Structure Prediction: AI-powered protein structure prediction reveals three-dimensional targets faster, helping researchers understand binding sites and identify opportunities for structure-based drug discovery.
Foundation Models: Biological foundation models learn broad molecular and biological patterns, supporting target identification, molecular design, screening, repurposing, and precision medicine applications.
AI-Powered Virtual Screening: AI rapidly evaluates enormous compound libraries, prioritizing molecules with promising target interactions and reducing experimental workloads during early drug discovery.
Multimodal AI; Multimodal AI combines molecular, genomic, imaging, clinical, and biological datasets, enabling researchers to develop more comprehensive predictions across discovery workflows.
AI Agents: AI agents increasingly coordinate research tasks, connect specialized models, interpret results, and support iterative discovery workflows with greater computational autonomy.
AI Drug Repurposing: AI analyzes relationships between diseases, drugs, genes, and biological pathways to uncover potential new therapeutic uses for existing medicines.
AI-Driven Clinical Trials: AI supports patient stratification, biomarker identification, trial design, and recruitment, helping researchers improve study efficiency while addressing complex clinical datasets.
AI-Human Collaboration: AI is increasingly positioned as a research partner rather than a replacement, combining computational predictions with experimental validation and scientific judgment.